These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 34268709)

  • 1. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.
    Anderson P; Austin J; Lofland JH; Piercy J; Joish VN
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
    Eichenfield LF; Liu J; Marwaha S; Piercy J; Sturm D; Anderson P
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):685-696. PubMed ID: 38453811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan.
    Wang C; Aranishi T; Reed C; Anderson P; Austin J; Davis VA; Quinones E; Piercy J
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):505-522. PubMed ID: 36515820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
    Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
    Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
    Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J
    J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician Perception of Disease Severity and Treatment Outcomes for Children and Adolescents with Atopic Dermatitis in Emerging Economies.
    Tang MBY; Fatani M; Wiggins S; Maspero J
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):999-1013. PubMed ID: 35349107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
    Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
    Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF;
    J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients.
    Torisu-Itakura H; Anderson P; Piercy J; Pike J; Sakamoto A; Kabashima K
    Curr Med Res Opin; 2022 Aug; 38(8):1401-1410. PubMed ID: 35787197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals.
    Gupta S; Garbarini S; Nazareth T; Khilfeh I; Costantino H; Kaplan D
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2057-2075. PubMed ID: 34648148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis.
    Wei W; Anderson P; Gadkari A; Blackburn S; Moon R; Piercy J; Shinde S; Gomez J; Ghorayeb E
    J Dermatol; 2018 Feb; 45(2):150-157. PubMed ID: 29131384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study.
    Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I
    Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study.
    Lio P; Mackie D; Bates D; Mulvihill E; Patel M; Kim Y; Shi V
    J Drugs Dermatol; 2023 Feb; 22(2):119-131. PubMed ID: 36745377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of Moderate to Severe Atopic Dermatitis in Adults from France, Italy, and the UK: Patient-Reported Outcomes and Treatment Patterns.
    Kleyn CE; Barbarot S; Reed C; Losi S; von Arx LB; Robert C; Anderson P; Grond S; Costanzo A
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1947-1965. PubMed ID: 35913548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.